Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

J. F. Nomdedéu; M. Hoyos; M. Carricondo; E. Bussaglia; C. Estivill; J. Esteve; M. Tormo; R. Duarte; O. Salamero; M. P.Q. De Llano; A. García; J. Bargay; I. Heras; J. M. Martí-Tutusaus; A. Llorente; J. M. Ribera; D. Gallardo; A. Aventin; S. Brunet; J. Sierra

doi:10.1038/leu.2013.111

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

J. F. Nomdedéu, M. Hoyos, M. Carricondo, E. Bussaglia, C. Estivill, J. Esteve, M. Tormo, R. Duarte, O. Salamero, M. P.Q. De Llano, A. García, J. Bargay, I. Heras, J. M. Martí-Tutusaus, A. Llorente, J. M. Ribera, D. Gallardo, A. Aventin, S. Brunet, J. Sierra

Research output: Contribution to journal › Article › Research › peer-review

43 Citations (Scopus)

Abstract

We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44±3 vs 36±3%, P=0.023; leukemia-free survival (LFS): 47±3 vs 36±4%, P=0.038; and cumulative incidence of relapse (CIR): 37±3 vs 47±4%, P=:0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59±4%, LFS:59±4% and CIR: 26±4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48±5%, LFS:41±4% and CIR: 45±4%); and Group 2 (WT1 >170.5 copies, 71 patients, OS: 23±6%, LFS: 19±7% and CIR: 68±8%) (P<0.001). Post-intensification samples distinguished three groups: patients with WT1 >100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 <10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30±7%, 59±4%, 72±5%), LFS (24±7%, 46±4%, 65±5%) and relapse probability (CIR 72±7%, 45±4%, 25±5%), all P<0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML. © 2013 Macmillan Publishers Limited.

Original language	English
Pages (from-to)	2157-2164
Journal	Leukemia
Volume	27
Issue number	11
DOIs	https://doi.org/10.1038/leu.2013.111
Publication status	Published - 1 Jan 2013

Keywords

minimal residual disease
molecular diagnostics
WT1

Access to Document

10.1038/leu.2013.111

Fingerprint Dive into the research topics of 'Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML'. Together they form a unique fingerprint.

Cite this

Nomdedéu, J. F., Hoyos, M., Carricondo, M., Bussaglia, E., Estivill, C., Esteve, J., Tormo, M., Duarte, R., Salamero, O., De Llano, M. P. Q., García, A., Bargay, J., Heras, I., Martí-Tutusaus, J. M., Llorente, A., Ribera, J. M., Gallardo, D., Aventin, A., Brunet, S., & Sierra, J. (2013). Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Leukemia, 27(11), 2157-2164. https://doi.org/10.1038/leu.2013.111

Nomdedéu, J. F. ; Hoyos, M. ; Carricondo, M. ; Bussaglia, E. ; Estivill, C. ; Esteve, J. ; Tormo, M. ; Duarte, R. ; Salamero, O. ; De Llano, M. P.Q. ; García, A. ; Bargay, J. ; Heras, I. ; Martí-Tutusaus, J. M. ; Llorente, A. ; Ribera, J. M. ; Gallardo, D. ; Aventin, A. ; Brunet, S. ; Sierra, J. / Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. In: Leukemia. 2013 ; Vol. 27, No. 11. pp. 2157-2164.

@article{e3b460e097e1451b94f225666b55cfbf,

title = "Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML",

abstract = "We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44±3 vs 36±3%, P=0.023; leukemia-free survival (LFS): 47±3 vs 36±4%, P=0.038; and cumulative incidence of relapse (CIR): 37±3 vs 47±4%, P=:0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59±4%, LFS:59±4% and CIR: 26±4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48±5%, LFS:41±4% and CIR: 45±4%); and Group 2 (WT1 >170.5 copies, 71 patients, OS: 23±6%, LFS: 19±7% and CIR: 68±8%) (P<0.001). Post-intensification samples distinguished three groups: patients with WT1 >100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 <10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30±7%, 59±4%, 72±5%), LFS (24±7%, 46±4%, 65±5%) and relapse probability (CIR 72±7%, 45±4%, 25±5%), all P<0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML. {\textcopyright} 2013 Macmillan Publishers Limited.",

keywords = "minimal residual disease, molecular diagnostics, WT1",

author = "Nomded{\'e}u, {J. F.} and M. Hoyos and M. Carricondo and E. Bussaglia and C. Estivill and J. Esteve and M. Tormo and R. Duarte and O. Salamero and {De Llano}, {M. P.Q.} and A. Garc{\'i}a and J. Bargay and I. Heras and Mart{\'i}-Tutusaus, {J. M.} and A. Llorente and Ribera, {J. M.} and D. Gallardo and A. Aventin and S. Brunet and J. Sierra",

year = "2013",

month = jan,

day = "1",

doi = "10.1038/leu.2013.111",

language = "English",

volume = "27",

pages = "2157--2164",

journal = "Leukemia",

issn = "0887-6924",

number = "11",

}

Nomdedéu, JF, Hoyos, M, Carricondo, M, Bussaglia, E, Estivill, C, Esteve, J, Tormo, M, Duarte, R, Salamero, O, De Llano, MPQ, García, A, Bargay, J, Heras, I, Martí-Tutusaus, JM, Llorente, A, Ribera, JM, Gallardo, D, Aventin, A, Brunet, S & Sierra, J 2013, 'Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML', Leukemia, vol. 27, no. 11, pp. 2157-2164. https://doi.org/10.1038/leu.2013.111

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. / Nomdedéu, J. F.; Hoyos, M.; Carricondo, M.; Bussaglia, E.; Estivill, C.; Esteve, J.; Tormo, M.; Duarte, R.; Salamero, O.; De Llano, M. P.Q.; García, A.; Bargay, J.; Heras, I.; Martí-Tutusaus, J. M.; Llorente, A.; Ribera, J. M.; Gallardo, D.; Aventin, A.; Brunet, S.; Sierra, J.

In: Leukemia, Vol. 27, No. 11, 01.01.2013, p. 2157-2164.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

AU - Nomdedéu, J. F.

AU - Hoyos, M.

AU - Carricondo, M.

AU - Bussaglia, E.

AU - Estivill, C.

AU - Esteve, J.

AU - Tormo, M.

AU - Duarte, R.

AU - Salamero, O.

AU - De Llano, M. P.Q.

AU - García, A.

AU - Bargay, J.

AU - Heras, I.

AU - Martí-Tutusaus, J. M.

AU - Llorente, A.

AU - Ribera, J. M.

AU - Gallardo, D.

AU - Aventin, A.

AU - Brunet, S.

AU - Sierra, J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44±3 vs 36±3%, P=0.023; leukemia-free survival (LFS): 47±3 vs 36±4%, P=0.038; and cumulative incidence of relapse (CIR): 37±3 vs 47±4%, P=:0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59±4%, LFS:59±4% and CIR: 26±4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48±5%, LFS:41±4% and CIR: 45±4%); and Group 2 (WT1 >170.5 copies, 71 patients, OS: 23±6%, LFS: 19±7% and CIR: 68±8%) (P<0.001). Post-intensification samples distinguished three groups: patients with WT1 >100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 <10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30±7%, 59±4%, 72±5%), LFS (24±7%, 46±4%, 65±5%) and relapse probability (CIR 72±7%, 45±4%, 25±5%), all P<0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML. © 2013 Macmillan Publishers Limited.

AB - We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44±3 vs 36±3%, P=0.023; leukemia-free survival (LFS): 47±3 vs 36±4%, P=0.038; and cumulative incidence of relapse (CIR): 37±3 vs 47±4%, P=:0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59±4%, LFS:59±4% and CIR: 26±4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48±5%, LFS:41±4% and CIR: 45±4%); and Group 2 (WT1 >170.5 copies, 71 patients, OS: 23±6%, LFS: 19±7% and CIR: 68±8%) (P<0.001). Post-intensification samples distinguished three groups: patients with WT1 >100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 <10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30±7%, 59±4%, 72±5%), LFS (24±7%, 46±4%, 65±5%) and relapse probability (CIR 72±7%, 45±4%, 25±5%), all P<0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML. © 2013 Macmillan Publishers Limited.

KW - minimal residual disease

KW - molecular diagnostics

KW - WT1

U2 - 10.1038/leu.2013.111

DO - 10.1038/leu.2013.111

M3 - Article

VL - 27

SP - 2157

EP - 2164

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -